Evidence map›Paper›PMID 28024684›Full record

ArticleJournal of dermatological science2017

Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1 clustering.

Kenji Yoshida, Ken Ishii, Atsushi Shimizu, Mariko Yokouchi, Masayuki Amagai, Ken Shiraishi, Yuji Shirakata, John R Stanley, Akira Ishiko

Abstract read
In one paragraph

Article in Journal of dermatological science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Ultrastructural skin alterations of healthy subjects withJournal of translational autoimmunity · 2023
    Article
  3. Dsg3 epitope-specific signalling in pemphigus.Frontiers in immunology · 2023
    Article
  4. Article
  5. Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways.The Journal of investigative dermatology · 2022
    Review
  6. Review
  7. Autoimmune Pemphigus: Latest Advances and Emerging Therapies.Frontiers in molecular biosciences · 2021
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Emerging treatment options for the management of pemphigus vulgaris.Therapeutics and clinical risk management · 2018
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Fogo selvagem: endemic pemphigus foliaceus.Anais brasileiros de dermatologia
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Kenji YoshidaDermatology, Toho University School of Medicine, Tokyo, Japan.
Ken IshiiDermatology, Toho University School of Medicine, Tokyo, Japan. Electronic address: ken.ishii@med.toho-u.ac.jp.
Atsushi ShimizuDermatology, Toho University School of Medicine, Tokyo, Japan.
Mariko YokouchiDermatology, Keio University School of Medicine, Tokyo, Japan.
Masayuki AmagaiDermatology, Keio University School of Medicine, Tokyo, Japan.
Ken ShiraishiDermatology, Ehime University School of Medicine, Ehime, Japan.
Yuji ShirakataDermatology, Ehime University School of Medicine, Ehime, Japan.
John R StanleyDermatology, University of Pennsylvania, Philadelphia, PA, USA.
Akira IshikoDermatology, Toho University School of Medicine, Tokyo, Japan.
Toho University · JPEhime University · JPKeio University · JPUniversity of Pennsylvania · US

Funding

Cloning and genetics of human pemphigus autoantibodiesR01AR052672 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI STANLEY, JOHN R · 2006 to 2015
$3.7M
NIAMS NIH HHS R01 AR052672
6 · The paper itself

Abstract

backgroundPemphigus foliaceus (PF) is an autoimmune blistering disease caused by autoantibodies (Abs) against desmoglein 1 (Dsg1). PF sera contain polyclonal Abs which are heterogeneous mixture of both pathogenic and non-pathogenic Abs, as shown by isolation of monoclonal Abs (mAbs).

objectiveTo investigate how pathogenic and non-pathogenic anti-Dsg1 Abs contribute to blister formation in PF.

methodsUsing organ-cultured human skin, we compared the effect of a single pathogenic anti-Dsg1 IgG mAb, a single non-pathogenic anti-Dsg1 IgG mAb, and their mixture on blister formation as analyzed by histology, subcellular localization of IgG deposits and desmosomal proteins by confocal microscopy, and desmosomal structure by electron microscopy. In addition, we measured keratinocyte adhesion by an in vitro dissociation assay.

results24h after injection, a single pathogenic anti-Dsg1 IgG caused a subcorneal blister with IgG and Dsg1 localized linearly on the cell surface of keratinocytes. A single non-pathogenic anti-Dsg1 IgG bound linearly on the keratinocytes but did not induce blisters. A pathogenic and a non-pathogenic IgG mAb injected together caused an aberrant granular pattern of IgG and Dsg1 in the lower epidermis with blister formation in the superficial epidermis. Electron microscopy demonstrated that the mixture of mAbs shortened desmosomal lengths more than a single mAb in the basal and spinous layers. Furthermore, although Dsg1 clustering required both cross-linking of Dsg1 molecules by the non-pathogenic IgG plus a pathogenic antibody, the latter could be in the form of a monovalent single chain variable fragment, suggesting that loss of trans-interaction of Dsg1 is required for clustering. Finally, a p38MAPK inhibitor blocked Dsg1 clustering. When pathogenic strength was measured by the dissociation assay, a mixture of pathogenic and non-pathogenic IgG mAbs disrupted keratinocyte adhesion more than a single pathogenic mAb. This pathogenic effect was only partially suppressed by the p38MAPK inhibitor.

conclusionThese findings indicate that a polyclonal mixture of anti-Dsg1 IgG antibodies enhances pathogenic activity for blister formation associated with p38MAPK-dependent Dsg1 clustering and that not only pathogenic antibodies but also non-pathogenic antibodies coordinately contribute to blister formation in PF.

Indexed as

AutoantibodiesCell AdhesionDesmoglein 1DesmosomesFluorescent Antibody TechniqueHumansImidazolesImmunoglobulin GKeratinocytesMicroscopy, ElectronOrgan Culture Techniquesp38 Mitogen-Activated Protein KinasesPemphigusPrimary Cell CulturePyridinesSingle-Chain Antibodies4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazoleAutoantibodiesDesmoglein 1DSG1 protein, humanImidazolesImmunoglobulin Gp38 Mitogen-Activated Protein KinasesPyridinesSingle-Chain AntibodiesDesmoglein 1Desmoglein 1 clusteringp38MAPK signalingPemphigus foliaceus

Identifiers

PMID28024684
PMCPMC5510496
OpenAlexW2566336483

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.